Braidwell LP Has $57.52 Million Position in TransMedics Group, Inc. $TMDX

Key Points

• Braidwell LP reduced its holdings in TransMedics Group, Inc. by 7.3%, now owning 854,884 shares valued at approximately $57.5 million, making it the 20th largest position in their portfolio.
• TransMedics Group reported earnings of $0.92 per share, significantly exceeding analyst expectations of $0.48, along with quarterly revenue of $157.37 million.
• Analysts have varying views on TransMedics, with Morgan Stanley raising its price target from $115 to $123, while Wall Street Zen downgraded the stock from a "buy" to a "hold" rating.

Braidwell LP lessened its stake in TransMedics Group, Inc. (NASDAQ:TMDX - Free Report) by 7.3% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 854,884 shares of the company's stock after selling 67,216 shares during the quarter. TransMedics Group comprises approximately 2.0% of Braidwell LP's investment portfolio, making the stock its 20th biggest holding. Braidwell LP owned approximately 2.53% of TransMedics Group worth $57,517,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in TMDX. Dimensional Fund Advisors LP grew its position in shares of TransMedics Group by 1,565.5% during the 4th quarter. Dimensional Fund Advisors LP now owns 269,825 shares of the company's stock worth $16,820,000 after buying an additional 253,624 shares during the period. Tower Research Capital LLC TRC grew its position in shares of TransMedics Group by 1,602.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 4,359 shares of the company's stock worth $272,000 after buying an additional 4,103 shares during the period. Stifel Financial Corp grew its position in shares of TransMedics Group by 20.8% during the 4th quarter. Stifel Financial Corp now owns 8,968 shares of the company's stock worth $559,000 after buying an additional 1,544 shares during the period. Northern Trust Corp grew its position in shares of TransMedics Group by 12.7% during the 4th quarter. Northern Trust Corp now owns 354,622 shares of the company's stock worth $22,111,000 after buying an additional 40,093 shares during the period. Finally, Freestone Grove Partners LP acquired a new stake in shares of TransMedics Group during the 4th quarter worth approximately $241,000. Institutional investors and hedge funds own 99.67% of the company's stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on TMDX. Oppenheimer lifted their price target on shares of TransMedics Group from $130.00 to $150.00 and gave the company an "outperform" rating in a research note on Tuesday, June 17th. Stifel Nicolaus began coverage on shares of TransMedics Group in a research note on Thursday. They issued a "hold" rating and a $115.00 price target on the stock. Canaccord Genuity Group lifted their price target on shares of TransMedics Group from $129.00 to $142.00 and gave the company a "buy" rating in a research note on Tuesday, July 15th. Wall Street Zen lowered shares of TransMedics Group from a "buy" rating to a "hold" rating in a research note on Saturday, August 30th. Finally, Morgan Stanley lifted their price target on shares of TransMedics Group from $115.00 to $123.00 and gave the company an "equal weight" rating in a research note on Friday, August 1st. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average price target of $122.11.

TransMedics Group Stock Down 0.0%

Shares of TMDX stock traded down $0.04 during trading on Friday, reaching $104.01. The company's stock had a trading volume of 996,736 shares, compared to its average volume of 877,429. The business has a fifty day moving average price of $118.07 and a 200-day moving average price of $104.09. The company has a quick ratio of 9.17, a current ratio of 9.86 and a debt-to-equity ratio of 1.61. The company has a market cap of $3.55 billion, a price-to-earnings ratio of 53.89 and a beta of 2.18. TransMedics Group, Inc. has a one year low of $55.00 and a one year high of $169.29.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 30th. The company reported $0.92 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.44. TransMedics Group had a net margin of 13.49% and a return on equity of 28.02%. The firm had revenue of $157.37 million for the quarter, compared to analyst estimates of $146.64 million. During the same period in the prior year, the firm posted $0.35 earnings per share. The company's quarterly revenue was up 37.7% compared to the same quarter last year. TransMedics Group has set its FY 2025 guidance at EPS. Analysts anticipate that TransMedics Group, Inc. will post 1 earnings per share for the current year.

Insider Activity at TransMedics Group

In related news, insider Anil P. Ranganath sold 686 shares of the company's stock in a transaction dated Monday, June 9th. The shares were sold at an average price of $139.80, for a total value of $95,902.80. Following the transaction, the insider directly owned 13,955 shares in the company, valued at approximately $1,950,909. This represents a 4.69% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 7.00% of the company's stock.

About TransMedics Group

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.